Articles by Ben Comer - Pharmaceutical Executive

ADVERTISEMENT

Articles by Ben Comer

Ben Comer

Entourage disconnected

Articles
Sickle Cell Disease In Three Acts
April 22, 2014

Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.

The Active Patient: Faces Of Change
February 1, 2014

Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.

Pharm Exec's Annual Industry Outlook 2014
January 21, 2014

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive — muddling through is so yesterday.

Biosimilars or Bust
January 21, 2014

Where are the biosimilars to help cut costs as the first wave of biologics, or complex, small molecule respiratory drugs, for example, go off patent? They've arrived in Europe, but the U.S. lags...

Brand vs. Generic: Physicians Weigh In
December 1, 2013

Why do some doctors prescribe more generic drugs than others?

Top Medical Innovations for 2014
November 1, 2013

At the conclusion of the Cleveland Clinic's Medical Innovations Summit each year, 10 innovative technologies are unveiled before the audience, and designated as new and revolutionary tools for the treatment of disease and disability.

2014 Pipeline Report: The Sprint to Value
November 1, 2013

Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.

Field Force Evolution: Adapting to a New Ecosystem
October 1, 2013

Environmental changes on all sides of professional sale are forcing biopharmaceutical companies to select for new traits in the makeup of the field force function.

Using Data to Influence Behavior and Predict Outcomes
October 1, 2013

Predictive analysis has been used to great effect in the finance, tech, retail, and telecoms industries. Can it also improve decision-making and health outcomes in life sciences?

ADVERTISEMENT

Click here